Business Wire

Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit

17.6.2026 15:00:00 CEST | Business Wire | Press Release

Share

Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability risk assessment to address the blind spot that autonomous AI exploitation tools are increasingly able to find. With mean time to exploit (MTTE) collapsing from months to days or hours, the unmanaged Java estate has become an urgent enterprise security vulnerability. Azul’s assessment gives DevOps and SecOps teams complete visibility into the hidden risks embedded in the runtime of their Java estate before threat actors get there first, and is designed to complement the broader security, licensing and compliance solutions and services delivered by Azul’s trusted partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617352753/en/

Azul's JVM Vulnerability Risk Assessment dashboard.

The Threat Landscape Has Transformed

For most of Java’s enterprise history, a sophisticated exploit required a sophisticated attacker. Zero-day discovery and weaponization were largely the domain of nation-states and elite offensive security teams. The barrier was expertise — deep JVM knowledge, reverse engineering and months of painstaking technical effort.

That barrier has collapsed. Anthropic’s Claude Mythos demonstrates that AI can autonomously uncover previously unknown vulnerabilities and generate working exploit paths at scale — without human expertise. What once required deep, specialized expertise can now be accomplished with little more than an advanced AI model and an API key.

The result is an expanding population of potential attackers. MTTE — once measured in months — can now collapse to days or hours. Meanwhile, most enterprises still patch non-critical Common Vulnerabilities and Exposures (CVEs) on a “best effort” basis, leaving extended windows of exposure between vulnerability disclosure and remediation. For large, complex Java estates with legacy versions in production, embedded or unmanaged JVMs and incomplete runtime visibility, that gap is a critical security and compliance liability.

The JVM Vulnerability Risk Assessment — See Everything, Prioritize What Matters

Azul’s JVM vulnerability risk assessment is available at no cost, direct from Azul and via select Azul partners. In a single engagement, organizations receive:

  • Executive-ready security dashboard: A visual summary of the entire Java estate, broken down by risk tier, publisher and Java version — designed for CxO-level consumption and board reporting.
  • Risk-by-version breakdown: Identification of the specific Java versions driving the highest exposure, so remediation effort can be directed where it matters most rather than spread uniformly.
  • Key Risk Indicators (KRIs) for AI-driven exploits: Visibility into which JVMs carry active Known Exploited Vulnerability (KEV) exposure — the highest-priority threat class recognized in the U.S. government’s CISA KEV catalog — as well as which instances are end-of-life or running below the current patch baseline.
  • Prioritized remediation roadmap: Concrete next steps ranked by impact, including which workloads to patch first, which to migrate off unsupported runtimes, and how to address extended support needs for legacy environments that cannot be immediately modernized.

“Through our strategic partnership with Azul, we significantly reduced our security risk level with our Java applications and Java-based infrastructure, which certainly helps me sleep better at night,” said Jenny Nelson, head of ICT & Digital at Newcastle City Council. “In addition, the benefits of switching to Azul Core as our JVM are clear. Our Java estate is now consistent, standardized, easier to maintain, and has brought a level of simplicity that’s a huge benefit to our organization.”

The assessment is purpose-built for the risk environment AI-driven attackers have created: one in which the gap between assumed security posture and actual security posture is measured not in audit findings, but in active exploits.

Why Security Patch Velocity is the Frontline Defense

Java’s quarterly updates are the primary mechanism by which known vulnerabilities are remediated. But in an environment where autonomous AI systems continuously discover new vulnerabilities or chain together previously known CVEs into exploits, the pace of standard patch deployment is no longer sufficient on its own. Azul’s enterprise Java platform addresses this challenge through a multi-layered approach designed for large, complex Java estates:

  • Stable Critical Patch Updates (CPUs): Quarterly, production-safe patches containing only current CVE fixes. Azul Core is the only OpenJDK distribution which provides security-only updates, intended for immediate deployment without disrupting live environments.
  • Out-of-cycle emergency fixes: As vulnerabilities are discovered which demand immediate remediation, Azul provides security-only emergency fixes, collaborating with the Java community to help ensure safe delivery.
  • Full-stack visibility: Azul surfaces every JVM instance across the enterprise estate, including embedded and unmanaged runtimes that standard asset discovery typically misses — closing the gaps before they can be exploited.

The zero-day problem remains the hardest frontier. No scanner, SIEM (Security Information and Event Management), or EDR (Endpoint Detection and Response) platform can detect a vulnerability that has not yet been disclosed. Against unknown exposure, organizations maintaining a fully current Java estate are materially harder to exploit as they continuously remove outdated runtimes and previously exposed attack surfaces from production, minimizing the footprint that agentic AI exploits can target.

Elevated Stakes for Regulated Enterprises

Organizations in financial services, healthcare, utilities and government face a compounding challenge. They operate some of the largest and most complex Java estates in existence, and they face the strictest regulatory obligations. Frameworks including PCI-DSS, SOX, HIPAA, DORA, NERC CIP and FedRAMP all require demonstrable visibility into deployed software versions, timely vulnerability remediation and documented patch history.

Autonomous AI exploitation tools do not distinguish between regulated and unregulated targets. But the consequences of a breach in a regulated environment — and the burden of demonstrating adequate security posture to auditors — make estate visibility and rapid CPU deployment not merely a best practice but a compliance requirement.

“Anthropic’s Mythos has shown that AI can now discover and weaponize vulnerabilities on its own — including flaws that survived decades of human review. That’s the real lesson for every CISO: the deep expertise that used to stand between attackers and your software estate is no longer a barrier,” said Scott Sellers, co-founder and CEO of Azul. “The unpatched JVM is already a growing liability, not a future one. Azul’s JVM vulnerability risk assessment was created to help security leaders find and close that exposure before AI-driven attackers can exploit it.”

Azul’s JVM vulnerability risk assessment maps JVM exposure, KEV risk and patch gaps across the entire enterprise Java estate and delivers a concrete remediation roadmap to close them. The assessment can be utilized as a standalone vulnerability analysis specific to a Java runtime estate or can be augmented into existing security, licensing and compliance solutions and services offered by Azul partners.

To understand your organization’s exposure, request a free JVM vulnerability risk assessment today.

FAQs

How do I find unmanaged or embedded JVMs across my enterprise Java estate?
Azul’s JVM vulnerability risk assessment surfaces every JVM instance across your environment — including embedded and unmanaged runtimes that standard asset discovery misses — and delivers a prioritized remediation roadmap to close the gaps.

How do I know which Java versions in my environment are the highest security risk?
Azul’s JVM vulnerability risk assessment breaks down your estate by risk tier, Java version and publisher, and identifies which JVMs carry active Known Exploited Vulnerability (KEV) exposure from the CISA KEV catalog.

What’s the best way to reduce the attack surface autonomous AI tools can exploit in my Java environment?
Azul continuously removes outdated runtimes and closes patch gaps across the entire Java estate — including legacy and unmanaged JVMs — minimizing the footprint autonomous AI exploitation tools can target.

Why are Critical Patch Updates (CPUs) important?
A CPU contains only security fixes, applied on top of the previous, field-stabilized release. That sets these updates apart from the Patch Set Updates (PSUs) that all other OpenJDK builds provide. PSUs bundle security updates, new features and bug fixes — typically measured in the hundreds — that demand far more testing before they can be safely deployed in production. Azul Core is the only OpenJDK distribution which provides CPUs, allowing teams to deploy urgent security fixes rapidly, with much lower risk of regression.

Why are unpatched Java environments a growing security liability?
Autonomous AI tools have collapsed mean time to exploit from months to days or hours, making unpatched JVMs and unmanaged runtimes an urgent liability — underscored by how quickly Mythos-class capability escaped its intended containment. Maintaining a current Java estate with full visibility is now the primary defense.

About Azul

Azul is the trusted leader in enterprise Java for today’s AI and cloud-first world. Its open source-based Java platform empowers organizations to optimize the entire Java lifecycle to accelerate performance, strengthen security, reduce licensing and cloud costs, and boost developer productivity. Azul powers mission-critical systems for 36% of the Fortune 100, 50% of the Forbes Top 10 World’s Most Valuable Brands, and the world’s top 10 financial trading companies. Learn more at azul.com and follow @azulsystems.​

View source version on businesswire.com: https://www.businesswire.com/news/home/20260617352753/en/

Contacts

Media Contact for Azul:
Treble -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftreblepr.com&es
heet=54554107&newsitemid=20260617352753&lan=en-US&anchor=Treble&index=5&md5=2834
90e2a2bc31dfc508c83d4c47b63f
Josh Georgiou
azul@treblepr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press Release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press Release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press Release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press Release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press Release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye